Median Technologies announced new and breakthrough results for its iBiopsy®? Lung Cancer Screening (LCS) AI/ML tech-based CADe/CADx1 Software as Medical Device (SaMD) to characterize malignant lung nodules in low dose CT scans (LDCT). New results released demonstrate considerable increase of Median's proprietary algorithms performance with a sensitivity2 of 96.5% for a specificity3 of 97.2% on end-to-end lung nodule detection and malignancy characterization.

These results complement the results released previously (March 22, 2022), which were based on a cohort of 1,760 patients and showed a 94.7% sensitivity at a 93.3% specificity. New results are calculated on a much larger cohort of 9,863 patients corresponding to 195,943 nodules (vs. 16,789 lung nodules in March 2022).

Consistent with previously released results, the performance corresponds to end-to-end detection and characterization at nodule level.